**Core Concept:** Cyclooxygenase (COX) is an enzyme involved in the conversion of arachidonic acid to prostaglandins, which are mediators of inflammation, pain, and platelet aggregation. Inhibition of COX can lead to reduced platelet aggregation and anti-inflammatory effects. Inhibition of COX can be reversible or irreversible. Reversible inhibitors are typically used for short-term therapeutic purposes, while irreversible inhibitors are typically used for long-term management.

**Why the Correct Answer is Right:** Aspirin (acetylsalicylic acid) is a selective inhibitor of COX-1, which is responsible for prostaglandin synthesis in platelets. Aspirin irreversibly acetylates serine residue in the COX active site, rendering the enzyme catalytically inactive. This leads to reduced platelet aggregation and anti-inflammatory effects. Aspirin is a popular choice for cardiovascular risk reduction and prevention of thrombotic events.

**Why Each Wrong Option is Incorrect:**

A. Nimesulide is a selective COX-2 inhibitor. While it can inhibit platelet cyclooxygenase, it does not inhibit platelet COX-1, resulting in a higher risk of gastrointestinal side effects due to COX-2's role in protecting the gastrointestinal mucosa.

B. Celecoxib is a selective COX-2 inhibitor. Similar to nimesulide, it inhibits COX-2 but spares COX-1, leading to a higher risk of gastrointestinal side effects.

C. Indomethacin is a non-selective COX inhibitor, meaning it inhibits both COX-1 and COX-2. However, it is neither selective enough to be used for cardiovascular risk reduction nor does it have a high gastrointestinal safety profile.

D. Salicylic acid is the active moiety of aspirin, which is why aspirin works as a COX inhibitor. Aspirin's irreversible inhibition of platelet COX-1 makes it an effective option for cardiovascular risk reduction and prevention of thrombotic events.

**Clinical Pearl:** Selective COX-2 inhibitors and non-selective NSAIDs are typically associated with higher gastrointestinal side effects due to inhibition of COX-1, which protects the gastrointestinal mucosa. Aspirin and its active moiety salicylic acid are specific COX inhibitors targeting COX-1 and COX-2 enzymes. Aspirin's irreversible inhibition of platelet COX-1 makes it an effective option for cardiovascular risk reduction and prevention of thrombotic events.